Disease mechanisms of glomerulonephritis: Chemokines and chemokine receptors

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 1, 2004, Pages 83-90

  Vielhauer, Volker ^a   Schlöndorff, Detlef ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; PROTEIN INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; EFFECTOR CELL; GLOMERULONEPHRITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; KIDNEY FAILURE; LEUKOCYTE MIGRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN SECRETION; REVIEW;

EID: 23744479543     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.07.001     Document Type: Review

References (20)

1. Luster, A.D. (1998) Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338, 436-445
2. Mackay, C.R. (2001) Chemokines: immunology's high impact factors. Nat. Immunol. 2, 95-101
3. Springer, T.A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301-314
4. Anders, H.J. et al. (2003) Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 63, 401-415
5. Segerer, S. et al. (2000) Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J. Am. Soc. Nephrol. 11, 152-176
6. Zernecke, A. et al. (2001) Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J. Immunol. 166, 5755-5762
7. Lloyd, C.M. et al. (1997) RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 185, 1371-1380
8. Topham, P.S. et al. (1999) Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J. Clin. Invest. 104, 1549-1557
9. Bird, J.E. et al. (2000) Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int. 57, 129-136
10. Anders, H.J. et al. (2003) CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J. Immunol. 170, 5658-5666
11. Anders, H.J. et al. (2003) Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. J. Am. Soc. Nephrol. 14, 317-326
12. Garcia, G.E. et al. (2003) Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. Am. J. Pathol. 162, 1061-1073
13. Anders, H.J. et al. (2002) A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. 109, 251-259
14. Vielhauer V. et al. (2004) CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephritic syndrome. Kidney Int. (in press)
15. Anders H.J. et al. (2004) Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J. Am. Soc. Nephrol. 15, 1504-1513
16. Shimizu, H. et al. (2003) Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J. Am. Soc. Nephrol. 14, 1496-1505
17. Wada, T. et al. (2004) Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 15, 940-948
18. Tesch, G.H. et al. (1999) Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J. Exp. Med. 190, 1813-1824
19. Proudfood, A.E. (2002) Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. 2, 106-115
20. Horuk, R. (2003) Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29, 369-375